NewAmsterdam Pharma Co N.V. (NAMS) stock: key figures, P/E, revenue and dividend
Health Care · Netherlands · ISIN USN625091095
NewAmsterdam Pharma Co N.V. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 22.50 m USD |
| Operating income | -225.68 m USD |
| EBIT | -231.41 m USD |
| Net income | -203.82 m USD |
| Diluted EPS – continuing operations | -1.72 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
More stocks
- Hainan Mining Co Ltd (601969.SS)
- Hypera SA (HYPMY)
- China Science Publishing & Media Ltd (601858.SS)
- Noah Holdings Ltd (NOAH)
- Youdao Inc (DAO)
- Pebblebrook Hotel Trust (PEB)
- nCino, Inc. (NCNO)
- Hangzhou Cable (603618.SS)
- Xinyi Solar Holdings Ltd (968.HK)
- BGI Genomics Co Ltd (300676.SZ)
- Anima Holding SpA (ANIM.MI)
- Pt Pradiksi Gunatama Tbk (PGUN.JK)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.